{"id":"NCT02720536","sponsor":"Novartis Pharmaceuticals","briefTitle":"Extended Evaluation of Deferasirox Film-coated Tablet (FCT) Formulation","officialTitle":"Open-label, Multicenter, Single Arm, Phase III Study to Collect Additional Safety and Efficacy Data With Deferasirox Film-coated Tablets in Patients Completing Study CICL670F2201","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-08-16","primaryCompletion":"2019-07-23","completion":"2019-07-23","firstPosted":"2016-03-28","resultsPosted":"2020-03-03","lastUpdate":"2020-03-03"},"enrollment":53,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Chronic Iron Overload"],"interventions":[{"type":"DRUG","name":"Deferasirox","otherNames":[]}],"arms":[{"label":"Deferasirox","type":"EXPERIMENTAL"}],"summary":"Extend evaluation of deferasirox film-coated tablet (FCT) formulation","primaryOutcome":{"measure":"Overview of Number of Participants With Adverse Events","timeFrame":"Baseline up to approximately 25 months","effectByArm":[{"arm":"Deferasirox","deltaMin":52,"sd":null}],"pValues":[]},"eligibility":{"minAge":"10 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":15},"locations":{"siteCount":14,"countries":["Austria","Greece","Italy"]},"refs":{"pmids":["32793403"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":13,"n":53},"commonTop":["Diarrhoea","Headache","Pyrexia","Nausea","Vomiting"]}}